Physician profile
John S Pollack
NPI 1881694933
$68,206.03
in general payments reported to CMS, 2019-2025
16 companies · $47.04 in 2025
The $47.04 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $18K · 2022: $110 · 2023: $93.56 · 2024: $15.72 · 2025: $47.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $42,300.00 | 2019 | |
| Genentech, INC. | $12,560.00 | 2020 | |
| Dutch Ophthalmic, USA | $4,500.00 | 2019 | |
| Alcon Vision LLC | $2,500.00 | 2020 | |
| F. Hoffmann-La Roche Ag | $2,221.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,886.92 | 2019-2022 | |
| Allergan, INC. | $1,220.28 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $624.44 | 2019 | |
| Genentech USA, INC. | $177.92 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $78.45 | 2023 | |
| Abbvie INC. | $37.79 | 2024-2025 | |
| Amgen INC. | $24.97 | 2025 | Pavblu |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.40 | 2019 | |
| Heidelberg Engineering, INC. | $19.43 | 2019 | |
| Coherus Oncology, INC. | $17.90 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.